Shareholder Activism As Public Venture Capital? In Some Cases, It’s Icahn’s Approach
This article was originally published in The Pink Sheet Daily
Executive Summary
We never meant to sell ImClone right away, and we don’t intend to flip Biogen Idec if we win the proxy fight, Icahn director says.
You may also be interested in...
Icahn And Eastbourne Win Some, Lose Some In Amylin Match
Dissident shareholders Carl Icahn and Eastbourne Capital Management have managed to snare two seats on Amylin's 12-person board of directors, enough to hold the firm's feet to the fire but not enough to command a major change of course
Icahn And Eastbourne Win Some, Lose Some In Amylin Match
Dissident shareholders Carl Icahn and Eastbourne Capital Management have managed to snare two seats on Amylin's 12-person board of directors, enough to hold the firm's feet to the fire but not enough to command a major change of course
Why Carl Icahn May Not Get His Way At Biogen Idec
Activist’s new plan could imply short-term gain and swift exit, may not sway shareholders in June vote, analysts say.